Lupus Ontario is excited to share share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a potential treatment for lupus nephritis, Gazyva is approved in 100 countries for various forms of lymphoma.
The primary endpoint of the Phase 3 REGENCY trial was met, meaning that complete renal response was seen in a higher proportion of people treated with Gazyva plus standard therapy (mycophenolate mofetil and glucocorticoids) at 76 weeks than those given standard therapy alone.
Read the full article here: Genetech – Press Release